Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

(2012) P. Wimberger et al.   ANNALS OF ONCOLOGY

Advances in bispecific biotherapeutics for the treatment of cancer

(2012) Chad May et al.   BIOCHEMICAL PHARMACOLOGY

Anti-CD20 Antibody Therapy for B-Cell Lymphomas

(2012) David G. Maloney   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab resistance

(2011) Andrew R. Rezvani et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Bispecific antibodies for cancer therapy

(2010) Patrick Chames et al.   mAbs

Structural and functional characterization of the trifunctional antibody catumaxomab

(2010) Dirk Chelius et al.   mAbs

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti‐CD20 × anti‐CD3), mediates efficient killing of B‐cell lymphoma cells even with very low CD20 expression levels

(2008) Michael Stanglmaier et al.   INTERNATIONAL JOURNAL OF CANCER